Fintel reports that on October 3, 2023, Barclays reiterated coverage of RELX PLC GBP.144397 (LSE:REL) with a Equal Weight recommendation. Analyst Price Forecast Suggests 3.85% Upside
Fintel reports that on October 4, 2023, Cantor Fitzgerald reiterated coverage of Merck (NYSE:MRK) with a Overweight recommendation. Analyst Price Forecast Suggests 24.09% Upside
Fintel reports that on October 4, 2023, B of A Securities maintained coverage of Alphabet Inc - (NASDAQ:GOOGL) with a Buy recommendation. Analyst Price Forecast Suggests 14.04% Upside
Fintel reports that on October 4, 2023, Barclays maintained coverage of PepsiCo (NASDAQ:PEP) with a Overweight recommendation. Analyst Price Forecast Suggests 21.83% Upside
Fintel reports that on October 3, 2023, Morgan Stanley maintained coverage of Atlantica Sustainable Infrastructure (NASDAQ:AY) with a Equal-Weight recommendation.
Fintel reports that on October 3, 2023, Morgan Stanley maintained coverage of NextEra Energy Partners LP - Unit (NYSE:NEP) with a Equal-Weight recommendation.
Fintel reports that on October 3, 2023, Raymond James maintained coverage of Maxeon Solar Technologies (NASDAQ:MAXN) with a Outperform recommendation.
Fintel reports that on October 3, 2023, Pickering Energy Partners initiated coverage of Enterprise Products Partners L P - Unit (NYSE:EPD) with a Outperform recommendation.
Fintel reports that on October 3, 2023, Capital One initiated coverage of Carisma Therapeutics (NASDAQ:CARM) with a Overweight recommendation.
Fintel reports that on October 3, 2023, JMP Securities reiterated coverage of PJT Partners Inc - (NYSE:PJT) with a Market Outperform recommendation.
Fintel reports that on October 3, 2023, B. Riley Securities maintained coverage of AMC Entertainment Holdings Inc - (NYSE:AMC) with a Neutral recommendation. Analyst Price Forecast Suggests 160.89% Upside
Fintel reports that on October 3, 2023, Susquehanna maintained coverage of Knight-Swift Transportation Holdings Inc - (NYSE:KNX) with a Neutral recommendation.
Fintel reports that on October 3, 2023, Benchmark reiterated coverage of Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Speculative Buy recommendation.